Clinical Trials
125 trialsA Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
TroFuse-031
Merck Sharp & Dohme LLC
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Sichuan Baili Pharmaceutical Co., Ltd.
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
PETRA
AstraZeneca
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
KEYVIBE-005
Merck Sharp & Dohme LLC
LIVIGNO-3
AbbVie
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
TROPiCS-04
Gilead Sciences
MEGACEP
UNICANCER
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Sun Yat-sen University
InPACT
Institute of Cancer Research, United Kingdom
ICRA
The Netherlands Cancer Institute
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
UNICANCER
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
IVY
Eli Lilly and Company
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
Canadian Cancer Trials Group
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
PIVOT-02
Nektar Therapeutics
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
Trial of NanoPac Focal Therapy for Prostate Cancer
NanOlogy, LLC